EE53 Cost-Minimization and Budget Impact Analysis of Venetoclax Versus Acalabrutinib for 1L and R/R Chronic Lymphocytic Leukemia in the Brazilian Public Healthcare System
| Autor: | Mattos, E.R., Follador, W., Campos, L., Antunes, R.C., Biella, C. |
|---|---|
| Zdroj: | In Value in Health June 2023 26(6) Supplement:S69-S69 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect